<DOC>
	<DOCNO>NCT02338440</DOCNO>
	<brief_summary>Veno-occlusive disease ( VOD ) hematopoietic stem cell transplantation ( HSCT ) remain major complication . VOD occur 11-31 % pediatric HSCT mortality reach 50 % . Prostaglandin E1 ( PGE1 ) report prevent relieve severity VOD Gluckman et al.. Lipo-PGE1 transporter PGE1 , superior concentrate PGE1 act prolong time . Because prolonged effective time , lipo-PGE1 act comparable effect 1/4~1/8 PGE1 dose . Empirically , pediatric HSCT center adopt lipo-PGE1 dose 1 mcg/kg/day ( 0.042 mcg/kg/hr ) , 1/7 dose recommend Gluckman , et al . This prospective study investigate concentration lipo-PGE1 preventive lipo-PGE1 empirical dose ( 1 mcg/kg/day ) .</brief_summary>
	<brief_title>Pharmacokinetic Study Lipo-PGE1 Prevention VOD After HSCT</brief_title>
	<detailed_description>Primary Objective : To evaluate pharmacokinetics lipo-PGE1 . Secondary objective : To evaluate relation lipo-PGE1 concentration VOD occurrence , severity . Inclusion criteria 1 . Patients undergo HSCT high risk VOD use low dose heparin . - high risk VOD : previous radiotherapy , liver function abnormality , child , condition regimen include busulfan total body irradiation - contraindication heparin : low platelet count , bleed tendency , allergy 2 . Patients ( one parent patient age &lt; 19 ) sign inform consent . Exclusion criteria 1 . Patient heart failure . 2 . Patient bleeding ( intracranial hemorrhage , gastrointestinal tract bleeding , hemoptysis ) . 3 . History hypersensitivity reaction shock lipo-PGE1 . 4 . Psychiatric disorder would preclude compliance . 5 . If clinician decides condition improper clinical study .</detailed_description>
	<mesh_term>Alprostadil</mesh_term>
	<criteria>1 . Patients undergo HSCT high risk VOD use low dose heparin . high risk VOD : previous radiotherapy , liver function abnormality , child , condition regimen include busulfan total body irradiation contraindication heparin : low platelet count , bleed tendency , allergy 2 . Patients ( one parent patient age &lt; 19 ) sign inform consent . 1 . Patient heart failure . 2 . Patient bleeding ( intracranial hemorrhage , gastrointestinal tract bleeding , hemoptysis ) . 3 . History hypersensitivity reaction shock lipoPGE1 . 4 . Psychiatric disorder would preclude compliance . 5 . If clinician decides condition improper clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>